La dipeptidil peptidasa 4 y su función frente a la COVID-19

Poma Castillo, Marisol; Bardales Zuta, Victor.
Rev. cuba. med ; 61(1)mar. 2022.
Artículo en Español | LILACS, CUMED | ID: biblio-1408980

Documentos relacionados

  1. Microbial gatekeepers: unraveling the role of the gut microbiota enzyme DPP4 in diabetes management.
  2. Evaluating Khaya senegalensis for Dipeptidyl Peptidase-IV Inhibition Using in Vitro Analysis and Molecular Dynamic Simulation of Identified Bioactive Compounds.
  3. [Role of Dipeptidyl peptidase inhibitors in lung ischemia-reperfusion injury].
  4. Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
  5. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
  6. Association of sodium-glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan.
  7. [Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)].
  8. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS).
  9. Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases.
  10. Study on the Mechanism of Interaction between Dipeptidyl Peptidase 4 and Inhibitory Peptides Based on Gaussian Accelerated Molecular Dynamic Simulation.